This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Stock Jumps 15.3%: Will It Continue to Soar?
by Zacks Equity Research
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
by Zacks Equity Research
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM
by Zacks Equity Research
The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.
Blueprint Medicines (BPMC) Down 9.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
by Zacks Equity Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics
by Zacks Equity Research
Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
by Zacks Equity Research
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU
by Zacks Equity Research
Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.
Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -18.34% and -39.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?